Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and ArchiveĀ 

Cipriano, C A; Issack, P S; Shindle, L; Werner, C M L; Helfet, D L; Lane, J M (2009). Recent advances toward the clinical application of PTH (1-34) in fracture healing. HSS Journal, 5(2):149-153.

Full text not available from this repository.

Abstract

PTH 1-34, an active form of parathyroid hormone, has been shown to enhance osteoblastic bone formation when administered as a daily subcutaneous injection. The effect of the intermittent administration of PTH (1-34) is an uncoupling of bone turnover with an increase in bone mass and density and decrease in risk of vertebral and nonvertebral fractures. While PTH (1-34) has been used clinically to increase bone mass and reduce fracture risk in postmenopausal women with osteoporosis, there is increasing evidence that PTH (1-34) may promote fracture healing. Animal studies have demonstrated accelerated callus formation with enhanced remodeling and biomechanical properties of the healing fracture. Given these effects, PTH (1-34) will likely be used clinically to enhance fracture union in poor healing situations such as osteoporosis and recalcitrant nonunions.

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Trauma Surgery
04 Faculty of Medicine > University Hospital Zurich > Division of Surgical Research
DDC:610 Medicine & health
Language:English
Date:2009
Deposited On:11 Feb 2010 19:45
Last Modified:23 Nov 2012 13:38
Publisher:Springer
ISSN:1556-3316
Publisher DOI:10.1007/s11420-009-9109-8
PubMed ID:19290582
Citations:Google Scholarā„¢

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page